NFKB1 and diffuse large B-cell lymphoma: Given the heterogeneity of NF-κB signaling in DLBCL, improving treatments in hematological malignancies using these next-generation targeted NF-κB inhibitors will require identification and targeting of a particular subunit or pathway in each specific patient.